pomalidomide has been researched along with Recrudescence in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.54) | 29.6817 |
| 2010's | 48 (73.85) | 24.3611 |
| 2020's | 16 (24.62) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, M; Baculi, F; Carmichael, J; Cathers, B; Correa, M; Daniel, T; Ebinger, K; Grant, V; Hamann, LG; Hansen, JD; Harris, R; Havens, CG; Huang, D; Kercher, T; Khambatta, G; LeBrun, LA; Leftheris, K; Leisten, J; Lopez-Girona, A; Mendy, D; Moghaddam, M; Nagy, MA; Narla, RK; Piccotti, J; Plantevin, V; Tang, Y; Vessey, R; Whitefield, B | 1 |
| Chim, CS; Kumar, S; Kwong, YL; Ngai, C; Wong, VKC | 1 |
| Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M | 1 |
| Abe, O; Ikemura, M; Kurokawa, M; Maki, H; Masamoto, Y; Miwa, A; Morita, K; Nakazaki-Watadani, K; Obo, T; Sumida, Y; Takami, H; Takayanagi, S; Tanaka, S; Yasaka, K | 1 |
| Binder, M; Brioli, A; Engelhardt, M; Ernst, T; Gengenbach, L; Heidel, FH; Hilgendorf, I; Hochhaus, A; Mancuso, K; Stauch, T; von Lilienfeld-Toal, M; Zamagni, E | 1 |
| Bulla, A; Conticello, C; Cupri, A; Curto Pelle, A; Di Giorgio, MA; Leotta, S; Leotta, V; Markovic, U; Martino, EA; Milone, G; Pirosa, MC; Sapienza, G; Scalise, L; Vaddinelli, D; Villari, L | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Ohara, S; Uchida, T | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Badillo, M; Berkova, Z; Chen, W; Feng, L; Jain, P; Manasanch, EE; Oriabure, O; Orlowski, RZ; Wang, M | 1 |
| Basset, M; Foli, A; Hegenbart, U; Kimmich, C; Mahmood, S; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Sachchithanantham, S; Schönland, SO; Sharpley, F; Wechalekar, A | 1 |
| Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D | 1 |
| Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M | 1 |
| Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K | 1 |
| Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM | 1 |
| Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG | 1 |
| Auguston, B; Chan, KL; Dodds, A; Harrison, S; Ho, PJ; Kwok, F; Lee, C; Mollee, P; Morris, K; Quach, H; Ramakrishna, R; Ramanathan, S; Rowlings, P; Scott, A; Stark, R; Taper, J; Taylor, K; Tiley, C; Warburton, P; Watson, AM; Weber, N | 1 |
| Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G | 1 |
| Hoy, SM | 1 |
| Berenson, JR; Bessudo, A; Cohen, A; Eshaghian, S; Flam, M; Klein, LM; Maluso, T; Nassir, Y; Rosen, PJ; Spektor, TM; Stampleman, L; Swift, RA; Vescio, R; Woliver, T | 1 |
| Sonneveld, P | 1 |
| Araujo, C; Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Mathiot, C; Moreau, P; Pegourie, B; Perrot, A; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Wetterwald, M | 1 |
| Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I | 1 |
| Aho, LS; Boulin, M; Caillot, D; Chretien, ML; Cransac-Miet, A; Favennec, C; Gueneau, P; Guy, J; Lafon, I | 1 |
| Bernatowicz, P; Charlinski, G; Dmoszynska, A; Grzasko, N; Guzicka-Kazimierczak, R; Janczarski, M; Jurczyszyn, A; Lech-Maranda, E; Swiderska, A; Szczepaniak, A; Szeremet, A; Waszczuk-Gajda, A; Wichary, R | 1 |
| Iwao, N; Kitahara, H; Koike, M; Komatsu, N; Ohta, Y; Watanabe, N | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Chao, NJ; Garrett, AH; Gasparetto, C; Green, MM; Kang, Y; Li, Z; Long, GD; McIntyre, JL; Rizzieri, DA; Sivaraj, D | 1 |
| Amatangelo, M; Bjorklund, C; Dimopoulos, MA; Flynt, E; Moreau, P; Ocio, EM; Peluso, T; Qian, X; Sternas, L; Thakurta, A; Towfic, F; Weisel, KC; Yu, X; Zaki, M | 1 |
| Gilmore, J; Hawkins, P; Lachmann, H; Mahmood, S; Manwani, R; Sachchithanantham, S; Sharpley, FA; Wechalekar, A; Whelan, C | 1 |
| Allangba, O; Araujo, C; Attal, M; Belhadj, K; Benboubker, L; Berge, B; Brechignac, S; Chaleteix, C; Eisenmann, JC; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Garderet, L; Glaisner, S; Hulin, C; Jaccard, A; Jourdan, E; Karlin, L; Kuhnowski, F; Lafon, I; Leleu, X; Lenain, P; Loiseau, HA; Macro, M; Marit, G; Mathiot, C; Mohty, M; Moreau, P; Orsini-Piocelle, F; Pegourie, B; Perrot, A; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Voog, E; Wetterwald, M | 1 |
| Gourd, E | 1 |
| Gong, CL; Liedtke, M; Studdert, AL | 1 |
| Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S | 1 |
| Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM | 1 |
| Ali, Z; Anwer, F; Hassan, H; Hassan, SF; Iftikhar, A; Kamal, A; Lakhani, M; Mushtaq, A; Raychaudhuri, S; Razzaq, F; Safdar, A; Sagar, F; Zahid, U; Zar, MA | 1 |
| Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ | 1 |
| Mahindra, A; Saini, N | 1 |
| Lokhorst, HM; van de Donk, NW | 1 |
| Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A | 1 |
| Mateos, MV; Ocio, EM; San Miguel, JF | 1 |
| Scott, LJ | 1 |
| Coleman, M; Mark, TM; Niesvizky, R | 1 |
| Barlogie, B; Crowley, J; Hansen, E; Hoering, A; Panozzo, S; Petty, N; Qu, P; Steward, D; Stratton, K; Usmani, SZ; Van Rhee, F; Waheed, S; Yaccoby, S; Zhang, Q | 1 |
| Kumar, S; Singla, A | 1 |
| Akehurst, R; Delforge, M; Dhanasiri, S; Dimopoulos, MA; Facon, T; Jacques, C; Lee, D; Morgan, G; Offner, F; Oriol, A; Palumbo, A; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Lonial, S; Usmani, SZ | 1 |
| Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Sternas, L; Teasdale, T; Weisel, KC; Yu, X; Zaki, MH | 1 |
| Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Hong, K; Ivanova, V; Jacques, C; Karlin, L; Knop, S; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Spencer, A; Sternas, L; Weisel, KC; Yu, X; Zaki, MH | 1 |
| Abonour, R; Bensinger, WI; Cohen, AD; Durie, BG; Gasparetto, C; Gomes, CL; Kaufman, JL; Lentzsch, S; Orlowski, RZ; Pascucci, N; Shah, JJ; Smith, DD; Stadtmauer, EA; Vogl, DT | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM | 1 |
| Biran, N; Duma, N; Richter, J; Siegel, D; Vesole, DH | 1 |
| Broijl, A; Sonneveld, P | 1 |
| Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U | 1 |
| Dimopoulos, MA; Gibson, CJ; Hong, K; Moreau, P; Saunders, O; Song, KW; Sternas, LA; Weisel, KC; Zaki, MH | 1 |
| Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M | 1 |
| Boyd, KD; Davies, FE; Dearden, CE; Kaiser, MF; Mohammed, K; Morgan, GJ; Pawlyn, C; Sriskandarajah, P | 1 |
| Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, M; Hayman, S; Kumar, SK; Lacy, M; Mikhael, J; Rajkumar, SV; Sinha, S | 1 |
| Ashan, G; Bartlett, JB; Clarke, IA; Dalgleish, AG; Fields, P; Knight, RD; Schey, SA; Streetly, M | 1 |
13 review(s) available for pomalidomide and Recrudescence
| Article | Year |
|---|---|
Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Recurrence | 2023 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide | 2018 |
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Multiple Myeloma; Recurrence; Thalidomide; Treatment Failure | 2017 |
Management of multiple myeloma in the relapsed/refractory patient.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2019 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome | 2013 |
Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2014 |
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; TOR Serine-Threonine Kinases | 2011 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease Progression; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2014 |
Treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Palliative Care; Plasma Cells; Precision Medicine; Proteasome Inhibitors; Recurrence; Thalidomide | 2016 |
20 trial(s) available for pomalidomide and Recrudescence
| Article | Year |
|---|---|
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2022 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2020 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Prospective Studies; Recurrence; Thalidomide | 2021 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Thalidomide | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2018 |
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Multiple Myeloma; Myocarditis; Progression-Free Survival; Proportional Hazards Models; Recurrence; Stevens-Johnson Syndrome; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Cross-Over Studies; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2015 |
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Thalidomide; Treatment Outcome | 2015 |
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Pneumonia; Pulmonary Embolism; Recurrence; Thalidomide; Time Factors | 2015 |
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lactones; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrroles; Recurrence; Thalidomide | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Cytokines; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2004 |
32 other study(ies) available for pomalidomide and Recrudescence
| Article | Year |
|---|---|
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Mice; Multiple Myeloma; Recurrence; Stereoisomerism; Treatment Failure; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Salvage Therapy; Thalidomide; Treatment Failure | 2023 |
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Recurrence; Remission Induction; Thalidomide; Transplantation, Homologous | 2019 |
[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2020 |
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Topics: Aged; Anti-Inflammatory Agents; Dexamethasone; Drug Resistance; Europe; Female; Follow-Up Studies; Hematologic Tests; Humans; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2020 |
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Body Weight; Case-Control Studies; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Histocompatibility Antigens Class I; Humans; Male; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Pharmaceutical Preparations; Receptors, Fc; Recurrence; Thalidomide; Time Factors | 2020 |
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Management; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2021 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Chromosomes, Human, Pair 1; Clinical Trials, Phase III as Topic; Dexamethasone; Febrile Neutropenia; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia; Randomized Controlled Trials as Topic; Recurrence; Risk; Salvage Therapy; Thalidomide; Trisomy | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Humans; Models, Economic; Multiple Myeloma; Oligopeptides; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States | 2017 |
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide | 2018 |
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Neutropenia; Recurrence; Registries; Retrospective Studies; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Odds Ratio; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Poland; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunologic Factors; Multiple Myeloma; Recurrence; Thalidomide | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computational Biology; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Immunologic Factors; Male; Middle Aged; Molecular Sequence Annotation; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2019 |
Combination therapy for first relapse of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Disease Progression; Humans; Multicenter Studies as Topic; Multiple Myeloma; Recurrence; Remission Induction; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome | 2018 |
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Multiple Myeloma; Quality of Life; Quality-Adjusted Life Years; Recurrence; Survival Analysis; Thalidomide | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluation; Drug Substitution; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Protease Inhibitors; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome, Human; Humans; Ikaros Transcription Factor; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-myc; Recurrence; Survival Analysis; Thalidomide; Translocation, Genetic; Whole Genome Sequencing | 2019 |
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2013 |
Pomalidomide. A last-line treatment option for multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Kidney Diseases; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Renal Insufficiency; Retreatment; Thalidomide; Treatment Outcome | 2016 |
The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Kidney Function Tests; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |